biotechnology

Analysts at BTIG laid out the bullish case for owning shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) — a "storied" company with a strong growth outlook. BTIG's Dane Leone initiates coverage of Vertex's stock with a Buy and $200 price target, on the thesis that...

The single hottest large-cap exchange-traded fund, the SPDR S&P Biotech (ETF) (NYSE: XBI), is up more than 40 percent since the start of 2017 and by 10 percent in the past two weeks alone. Many investors aren't willing to assume the inherent risk that comes with investing in highly volatile...

Analysts at H.C. Wainwright & Co. continue to see Ligand Pharmaceuticals Inc. (NASDAQ: LGND) as a "core long term holding" for investors. The firm's Joseph Pantginis initiated coverage of the biopharmaceutical company with a Buy rating and $150 price target, mostly due to the company's business...

Agilent Technologies Inc (NYSE: A)'s earnings report was strong enough for Deutsche Bank's Dan Leonard to maintain a Buy rating on the stock with a price target boosted from $66 to $68. Agilent's fiscal third-quarter earnings report highlighted the company's strong end market exposures, product...

Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) is clinical-stage biopharmaceutical company whose lead pivotal-stage product candidate, eptinezumab, is used for the treatment of migraines. The company is also one that ordinary investors should consider passing on, according to CNBC's Jim...

Shares of Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) continued trading higher on Tuesday after Monday's strong gains. Cyclacel issued a press release over the weekend which detailed a presentation from independent investigators. The investigation highlighted the therapeutic potential of...

As was widely documented, the healthcare sector languished last year thanks in large part to presidential election rhetoric in which both candidates excoriated biotechnology and pharmaceuticals for high drug prices. The Health Care SPDR (ETF) (NYSE: XLV), the largest healthcare exchange-traded fund...

The bottom half of December will prove to be a busy one for the biotechnology sector. Below are six biotech companies with catalysts still ahead for the end of the year. Roche Holding Roche Holding Ltd. (ADR) (OTC: RHHBY)'s Genentech unit's OCREVUS's Prescription Drug User Fee Act (PDUFA) date is...

Juno Therapeutics Inc (NASDAQ: JUNO) announced late Thursday it has received notice from the U.S. Food and Drug Administration that it has placed a clinical hold on its Phase II clinical trial of JCAR015 in patients with relapsed or refractory B cell acute lymphoblastic leukemia. The trial,...

In what has been a trying year for biotechnology stocks and exchange-traded funds, traders and investors are likely tired of hearing about when this group is finally going to deliver some legitimate upside. Although the popular triple-leveraged biotech ETF Direxion Daily S&P Biotech Bull 3X...